At a Glance
- Company: Create Medicines
- Location: San Francisco, US
- Funding: $122 million Series B
- Focus area: In vivo CAR-T via mRNA electroporation
- Next steps: Preclinical IND-enabling work, first-in-human (2027)
What happened?
Create Medicines raised $122 million in Series B financing to fund its early pipeline of in vivo CAR-T cell therapies, which use mRNA and electroporation to turn patient cells against cancer without ex vivo manufacturing. The round was led by new investors including Arch Venture Partners and existing backers.
Why does it matter?
Current CAR-T therapies require harvesting, engineering and reinfusing patient T cells—a costly, time-intensive process with limited scalability. Create’s in vivo approach aims to deliver CAR-T directly into the body, potentially lowering cost, shortening timelines and making cell therapy accessible to more patients.
Who’s behind it?
Create Medicines is a San Francisco-based biotech founded by former San Francisco State University researchers. The company leverages mRNA electroporation technology to engineer T cells in the body, with a focus on liquid and solid tumours.
How was it achieved?
Create uses mRNA encoding chimeric antigen receptors delivered via electroporation to program T cells directly in the patient’s bloodstream or tumour microenvironment. The approach avoids complex ex vivo manufacturing, and early experiments show sustained CAR-T expression and anti-tumour activity in preclinical models.
What’s next?
The company plans to advance its lead candidate into IND-enabling studies and aim for first-in-human trials in 2027. The Series B proceeds will also support discovery work on additional targets and diseases, including solid tumours.